Author

F. Lynce

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

D. A. Dillon· 2 shared J. M. Rosenbluth· 2 shared B. Y. Nabet· 1 shared C. Biellak· 1 shared E. J. Kim· 1 shared E. Murray· 1 shared H. Hammerlindl· 1 shared H. P. Nguyen· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. A. Dillon

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression

H. P. Nguyen, R. Sheng, E. Murray, Y. Ito, M. Bruck, C. Biellak, K. An, F. Lynce, D. A. Dillon, M. J. M. Magbanua, L. A. Huppert, H. Hammerlindl, L. Esserman, J. M. Rosenbluth, N. Ahituv

The paper shows engineered adipocytes can suppress cancer progression by competing for nutrients in multiple cancer types.

bioRxiv · Mar 28, 2023 · PreprintCancer Biology

T cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL-1 and TNFa Inflammation.

N. W. Cho, S. M. Guldberg, B. Y. Nabet, J. Z. Yu, E. J. Kim, K. J. Hiam-Galvez, J. L. Yee, R. DeBarge, I. Tenvooren, N. A. Ashitey, F. Lynce, D. A. Dillon, J. M. Rosenbluth, M. H. Spitzer

The paper identifies a novel mechanism of ICI resistance where T cells drive inflammatory resistance via IL-1 and TNF in tumors, with implications for therapy.

bioRxiv · Sep 20, 2022Immunology